Harmony Biosciences (HRMY) awards 212,241 stock options to COO Anastasiou
Harmony Biosciences (HRMY) has granted its Chief Operating Officer, Peter Anastasiou, 212,241 stock options with an exercise price of $27.74 per share, set to expire on April 2, 2036. The options will vest over time, with 25% vesting on April 2, 2027, and the remainder vesting quarterly thereafter, contingent on his continued employment. This grant is a compensation-related acquisition and not an open-market transaction.
Harmony Biosciences (HRMY) director granted 17,710 stock options at $27.74 strike
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi received a grant of 17,710 stock options with an exercise price of $27.74 per share, set to expire on April 2, 2036. This compensation-related award will vest in 36 equal monthly installments starting May 2, 2026. The Form 4 filing indicates this is a grant and not an open-market transaction, bringing Ignelzi's direct stock option holdings to 17,710 shares.
Harmony Biosciences Appoints Peter Anastasiou as Chief Operating Officer
Harmony Biosciences (HRMY) has appointed board member Peter Anastasiou as Chief Operating Officer and Senior Executive Vice President, effective April 2, 2026. This move aligns his experience with daily operations and involves a comprehensive employment package. Additionally, the company appointed Troy Ignelzi to the board and confirmed long-serving director Antonio Gracias will not seek re-election, with Geno J. Germano nominated in his place, aiming to refresh governance and expertise for future growth.
A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness
Harmony Biosciences Holdings (HRMY) has experienced mixed short-term share price movements, showing a small gain over the past week but declines over the past month and three months. Despite a US$1.6 billion market value and significant revenue and net income, the stock's valuation is being reassessed due to fading momentum and potential risks to its rare neurological disease franchise. Analysts currently consider HRMY undervalued with a fair value of $47.30, based on expected revenue gains, expanding margins, and pipeline catalysts, though this confidence could be tested by legal or regulatory setbacks.
Harmony Biosciences Appoints Peter Anastasiou as Chief Operating Officer
Harmony Biosciences has appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026. This move aligns Anastasiou's extensive biotech experience with the company's day-to-day operations, accompanied by a comprehensive compensation package. Additionally, Harmony is refreshing its board with the appointment of Troy Ignelzi and the nomination of industry veteran Geno J. Germano, following the departure of Antonio Gracias, to strengthen governance and support future growth.
Harmony Biosciences Holdings, Inc. recently announced two significant personnel changes aimed at strengthening the company’s governance and strategic leadership.
Harmony Biosciences Holdings, Inc. has announced two key personnel changes to enhance its governance and strategic leadership. The company appointed a new core executive to its management team and new members to its board of directors. These changes are expected to drive future business expansion and innovative research and development initiatives.
Harmony Biosciences Holdings, Inc. recently announced two significant personnel changes aimed at strengthening the company’s governance and strategic leadership.
Harmony Biosciences Holdings, Inc. has announced two significant personnel changes, including the appointment of a new core executive to its management team and new members to its board of directors. These strategic appointments are intended to enhance the company's governance and leadership. The changes are expected to drive business expansion and foster innovative research and development.
Harmony Biosciences (HRMY) names new COO and reshapes its board
Harmony Biosciences Holdings, Inc. has appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026, with an annual base salary of $600,000 and significant stock options. Concurrently, Troy Ignelzi has been appointed as a Class III director, filling the vacancy left by Anastasiou's board resignation, and Antonio Gracias will not seek re-election. The company also nominated Geno J. Germano for election to the board at its 2026 annual meeting, strengthening its leadership team for future growth.
Harmony Biosciences Holdings, Inc. recently announced two significant personnel changes aimed at strengthening the company’s governance and strategic leadership.
Harmony Biosciences Holdings, Inc. has announced significant personnel changes, including a new core executive and new board members. These appointments are intended to enhance the company's governance and strategic leadership, bringing fresh momentum to business expansion and innovative research and development. The changes are expected to strengthen the company’s future growth prospects.
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the event will be available on the investor page of the Harmony Biosciences website. Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases.
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
Harmony Biosciences Holdings, Inc. will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the event will be available on the company's investor relations website. Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases.
Wedge Capital Management L L P NC Buys New Position in Harmony Biosciences Holdings, Inc. $HRMY
Wedge Capital Management L L P NC has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 88,897 shares valued at approximately $3.33 million. This comes as institutional ownership in Harmony Biosciences stands at 86.23%, with other firms like SG Americas Securities LLC also significantly increasing their stakes. Despite missing Q4 EPS estimates, Harmony Biosciences reported a revenue beat, though analyst ratings are mixed with a consensus "Hold" rating.
Harmony Biosciences stock faces headwinds amid analyst downgrade and Q4 earnings miss
Harmony Biosciences (NASDAQ:HRMY) faces new challenges after Zacks Research downgraded its stock to 'strong sell' due to a significant Q4 earnings miss, despite revenue slightly exceeding forecasts. The biopharmaceutical company, focused on rare neurological disorders, saw its shares trade below key moving averages, signaling technical weakness. Investors are closely monitoring pipeline progress for WAKIX and other assets, along with regulatory catalysts, as the company navigates a competitive market with a focus on liquidity and manageable debt.
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "hold" to a "strong sell" rating following a Q4 earnings miss, where EPS was significantly below estimates. Despite this, the consensus analyst rating for the stock remains "Hold" with an average price target of $42.67. Insider selling by CFO Sandip Kapadia was noted, while institutional investors have actively traded the stock, with some significantly increasing their stakes.
Vanguard disaggregates holdings after realignment — Harmony Biosciences (HRMY)
Vanguard has filed an amended Schedule 13G/A for Harmony Biosciences (HRMY), reporting zero beneficial ownership of common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538. The filing clarifies that Vanguard no longer holds direct beneficial ownership over these securities.
SG Americas Securities LLC Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY
SG Americas Securities LLC significantly increased its stake in Harmony Biosciences Holdings, Inc. ($HRMY) by over 4,100% in Q4 2025, acquiring 961,667 shares valued at nearly $36 million. This increase comes despite Harmony Biosciences missing EPS expectations in its latest quarter, though revenue grew by 21.1%. Analyst sentiment for HRMY is mixed, with a consensus "Hold" rating and an average target price of $42.67.
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disease market shifts
Harmony Biosciences is facing increased scrutiny over its pipeline strategy following its 2025 acquisition of Epygenix Therapeutics, especially in light of Polaryx Therapeutics' recent 10-K filing. The filing reveals overlapping rare disease programs linked to Mstone Partners, the seller of Epygenix, raising concerns about integration challenges, competitive market fragmentation, and resource allocation in the orphan drug sector. US investors are closely monitoring how Harmony will navigate these complexities and execute its expanded neurology orphan drug pipeline.
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disease market shifts
Harmony Biosciences is facing scrutiny over its pipeline following the 2025 acquisition of Epygenix Therapeutics, as Polaryx Therapeutics' recent 10-K filing reveals overlapping rare disease programs with their shared backer, Mstone Partners. US investors are closely monitoring how Harmony navigates integration challenges, competitive pressures, and the need to differentiate its assets in the neurology orphan drug market. The article highlights the strategic implications of these connections for Harmony's stock performance and resource allocation.
HRMY Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Harmony Biosciences Holdings Inc's (HRMY) financial performance, focusing on its profitability margins and comparing them to competitors DMRA and AGIO. HRMY maintains strong gross, operating, and net margins, along with a healthy Return on Equity, indicating efficient operations and shareholder value generation. The company's market capitalization of $1.60B positions it significantly within its sector.
HRMY Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for HRMY (Harmony Biosciences Holdings Inc), detailing past quarterly results, future revenue and EPS estimates for Q1 2026, and how stock price correlates with earnings forecast revisions. It also examines historical stock reactions to earnings reports and key highlights from recent earnings, suggesting potential buying opportunities due to recent stock price changes.
Are options traders betting on a big move in Harmony Biosciences stock?
The article discusses unusual options activity in Harmony Biosciences (HRMY) stock, specifically highlighting high put and call option volumes with significant open interest. This activity suggests that options traders may be anticipating a substantial price movement for Harmony Biosciences.
Are Options Investors Anticipating Significant Volatility in Harmony Biosciences Shares?
Harmony Biosciences (HRMY) has shown significant options market activity, particularly with its April 17, 2026 $5.00 Call option exhibiting high implied volatility, suggesting traders expect substantial future price swings. Despite this, analyst sentiment is cautious, with a Zacks Rank #3 (Hold) and lowered earnings estimates, which could create opportunities for options traders to sell premium. The article highlights that implied volatility is one of many factors to consider in options trading.
Are Options Traders Betting on a Big Move in Harmony Biosciences Stock?
Options traders are showing increased interest in Harmony Biosciences (HRMY) stock, particularly with the Apr 17, 2026 $05.00 Call, due to high implied volatility. While this suggests expectations of a significant price movement, analysts currently rate Harmony Biosciences as a Zacks Rank #3 (Hold) with recent downward revisions in earnings estimates. This situation indicates potential strategies for options traders to sell premium, betting that the stock's movement will be less than the implied volatility suggests.
(HRMY) Movement as an Input in Quant Signal Sets
Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) shows a neutral sentiment across all trading horizons, suggesting a wait-and-see approach. The article outlines three distinct AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different risk profiles. Key support at $27.49 and resistance at $39.22 are identified, with a breakdown currently underway and elevated downside risk.
Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline
Harmony Biosciences (HRMY) is aiming for significant growth in WAKIX revenue, projecting $1 billion to $1.04 billion in 2026, driven by higher demand, increased market share, and label expansion for idiopathic hypersomnia. The company also plans to expand its late-stage central nervous system (CNS) pipeline through business development and internal programs. Additionally, Harmony Biosciences anticipates WAKIX to achieve $700–$720 million in revenue for 2024 and provided insight into its long-term financial strategy.
Deutsche Bank cuts PT on Harmony Biosciences Holdings (HRMY) to $30 from $31
Deutsche Bank has adjusted its price target for Harmony Biosciences Holdings (HRMY) from $31 to $30. This rating change indicates a revised outlook on the company's stock by the financial institution.
HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Harmony Biosciences Holdings (HRMY) SEC filings, including 10-K, 10-Q, and 8-K reports, offering insights into the company's financial performance, clinical developments, and strategic announcements related to their WAKIX franchise and CNS pipeline. The platform also includes AI-powered summaries of these documents and reports on insider and executive transactions. Recent filings detail financial results, clinical milestones for various drug candidates, and insider stock dispositions by key stakeholders.
Harmony Biosciences Reports 2025 Revenue Growth, Issues 2026 Outlook
Harmony Biosciences Holdings, Inc. reported strong financial results for 2025, with fourth-quarter net product revenue of $243.8 million and full-year revenue of $868.5 million for its narcolepsy drug WAKIX, representing significant year-over-year growth. The company expects WAKIX to achieve blockbuster status in 2026, with revenue guidance between $1.0 billion and $1.04 billion. Harmony Biosciences is also expanding its product pipeline with new formulations of pitolisant and a novel orexin-2 receptor agonist.
Does Mixed Q4 Results and Reaffirmed WAKIX Guidance Change The Bull Case For Harmony Biosciences (HRMY)?
Harmony Biosciences Holdings reported mixed Q4 2025 results with lower quarterly EPS but higher full-year net income, while reaffirming its 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion. The FDA's approval of WAKIX for pediatric narcolepsy is a key growth driver, but the company's reliance on a single asset remains a significant risk. The varied interpretations of these results by analysts suggest differing views on Harmony's future growth and valuation.
Does Mixed Q4 Results and Reaffirmed WAKIX Guidance Change The Bull Case For Harmony Biosciences (HRMY)?
Harmony Biosciences reported mixed Q4 2025 results with lower net income but a rise in full-year net income to US$158.69 million, alongside reaffirmed 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion. The FDA's approval of WAKIX for pediatric narcolepsy patients aged 6 and older expands its market, supporting the short-term growth story. However, the company remains heavily reliant on WAKIX, raising questions about its long-term earnings sustainability given potential competition and patent timelines.
HRMY Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Harmony Biosciences Holdings Inc (HRMY), indicating a "Strong Sell" consensus based on various indicators. Reviewing moving averages, momentum indicators, and support/resistance levels, the analysis suggests a bearish outlook for the stock. Key metrics include a MACD of -2.296, an RSI of 31.888 (Neutral), and the stock trading below its 200-day moving average.
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. will participate in several upcoming investor conferences, including the Leerink Partners Global Healthcare Conference, UBS Biotech Summit, and Barclays 28th Annual Global Healthcare Conference, all held in Miami, FL. The company, focused on rare neurological diseases, also announced strong financial results for 2025 and recent FDA approval for WAKIX® for pediatric narcolepsy. Harmony Biosciences is committed to developing innovative therapies and fostering a better future for patients.
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences announced its management team will attend three investor conferences in Miami, FL in March 2026: the Leerink Partners Global Healthcare Conference, the UBS Biotech Summit (both on March 9), and the Barclays 28th Annual Global Healthcare Conference (on March 10). The company specializes in developing and commercializing therapies for rare neurological diseases.
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its management team will attend three investor conferences in Miami, FL in March 2026: the Leerink Partners Global Healthcare Conference, the UBS Biotech Summit, and the Barclays 28th Annual Global Healthcare Conference. The company specializes in developing and commercializing therapies for rare neurological diseases.
A Look At Harmony Biosciences (HRMY) Valuation After Guidance Reaffirmation And New Pediatric WAKIX Approval
Harmony Biosciences (HRMY) has reaffirmed its 2026 WAKIX revenue guidance and received FDA approval for pediatric cataplexy in narcolepsy, yet its stock performance has been weak. Despite a fair value estimate of $47.30, suggesting undervaluation, this projection relies on the continued exclusivity of WAKIX and successful progression of late-stage assets. The article advises investors to review all facts before making investment decisions and offers resources for further research into undervalued stocks and strong fundamentals.
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
Deutsche Bank has adjusted its price target for Harmony Biosciences Holdings (HRMY) to $30 from $31, maintaining a Hold rating after the company's fiscal Q4 report. Harmony Biosciences reported strong 2025 financial results, with significant revenue growth for WAKIX and projections to achieve blockbuster status in 2026. Despite its potential, the article suggests that certain AI stocks might offer greater upside and less downside risk.
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
Deutsche Bank has adjusted its price target for Harmony Biosciences Holdings (HRMY) from $31 to $30, while reiterating a Hold rating on the stock. This revision follows the company's strong fiscal Q4 2025 report, which showed significant revenue growth for its product WAKIX and projected blockbuster status for 2026. Harmony Biosciences, a pharmaceutical company focused on neurological disorders, continues to demonstrate commercial strength with consistent patient adds for WAKIX.
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
Deutsche Bank has adjusted its price target for Harmony Biosciences Holdings (HRMY) to $30 from $31, maintaining a Hold rating. This update follows Harmony Biosciences' strong Q4 2025 financial results, which included 21% year-over-year revenue growth for WAKIX and a projection to exceed $1 billion in revenue for WAKIX in 2026. The company reported continued commercial strength with six consecutive years of revenue growth and profitability.
12 Cheap Biotech Stocks to Buy Now
This article identifies cheap biotech stocks to buy now, focusing on Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) as an example. It details HRMY's strong 2025 financial results, including significant revenue growth for its drug WAKIX® and projections to exceed $1 billion in revenue in 2026. The report also mentions Deutsche Bank's reiterated Hold rating and adjusted price target for HRMY.
State of New Jersey Common Pension Fund D Invests $1.57 Million in Harmony Biosciences Holdings, Inc. $HRMY
The State of New Jersey Common Pension Fund D recently invested $1.57 million in Harmony Biosciences by acquiring 57,041 shares in the third quarter. Institutional investors now collectively own 86.23% of Harmony Biosciences. Despite some insider selling, the company maintains a "Moderate Buy" consensus rating from analysts, though its Q4 EPS missed estimates.
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Truist Securities downgraded Harmony Biosciences Holdings, Inc. (HRMY) from Buy to Hold following patent trial developments that suggest a high risk of generic rivals entering the market before 2029. This downgrade occurred despite the recent FDA approval of Harmony's WAKIX for treating cataplexy in children with narcolepsy. The company specializes in therapies for rare neurological disorders, but the analyst believes other AI stocks offer better upside potential with less risk.
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Truist Securities has downgraded Harmony Biosciences Holdings, Inc. (HRMY) from Buy to Hold after a patent trial against AET Pharma concluded, raising concerns about potential generic competition for its Wakix franchise before 2029. This downgrade comes despite the recent FDA approval of Wakix for treating cataplexy in children with narcolepsy, expanding its market. The analyst suggests that while HRMY has potential, other AI stocks offer greater upside and less risk.
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval
Harmony Biosciences (HRMY) saw its stock drop 20.1% despite reaffirming its 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion and receiving FDA approval for pediatric cataplexy in narcolepsy patients. The company reported Q4 2025 net income of US$22.49 million and full-year net income of US$158.69 million, while also making progress on its intellectual property framework for WAKIX. Investors are weighing these positive developments against the risks of single-asset concentration and unresolved IP disputes.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts
Harmony Biosciences (NASDAQ:HRMY) has received a "Moderate Buy" consensus rating from analysts, with a 1-year average price target of $42.67. The company's Q4 revenue grew 21% to $243.8 million, exceeding estimates, and it reiterated its 2026 revenue guidance of over $1 billion for WAKIX, despite an EPS miss of $0.38 against an expected $0.84. Insider selling, including by the CFO and CEO, totaled around $1.93 million last quarter, though insiders still hold approximately 23.6% of the company.
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY)
Healthcare sector analysts have recently provided new ratings for ProQR (PRQR), Immunic (IMUX), and Harmony Biosciences Holdings (HRMY). ProQR received a Strong Buy consensus with an $8.33 price target, and Immunic also garnered a Strong Buy with a $5.50 price target. Harmony Biosciences Holdings was downgraded to Hold by Truist Financial and UBS, holding a Moderate Buy consensus with a $45.60 price target.
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry
UBS has lowered its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) from $46 to $36, while maintaining a Neutral rating. This adjustment comes after the company reached new settlement agreements allowing generic versions of Wakix to launch four months earlier than previously expected. Despite a recent 5% stock recovery, the stock remains down 20% over the past week, with UBS citing positive investor sentiment from the additional generic settlements as the cause for the recent rebound.
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility
Harmony Biosciences Holdings, Inc., a small-cap pharmaceutical and biotechnology company, has recently had its stock evaluation revised. Despite facing significant stock volatility and a 22.99% decline over the past year, the company boasts a P/E ratio of 8 and a strong return on capital employed (ROCE) of 53.26%, presenting a favorable valuation compared to its peers. Its current stock price is $26.87.
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS
UBS analyst So Youn Shim has lowered the price target for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) from $46.00 to $36.00. This adjustment was reported on February 25, 2026, at 8:03 AM EST. The full details of this analysis are available to premium subscribers.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences reported strong financial results for Q4 and full year 2025, with WAKIX net product revenue reaching $243.8 million and $868.5 million respectively. The company forecasts WAKIX to achieve blockbuster status in 2026 with $1 billion to $1.04 billion in net revenue, driven by sustained demand and upcoming life cycle management strategies. Harmony is also advancing a robust late-stage pipeline, including 5 ongoing Phase III trials for various CNS indications and new pitolisant formulations.
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Harmony Biosciences announced strong financial results for 2025, with WAKIX net revenue reaching $868.5 million and reiterating its 2026 net revenue guidance of $1.0 to $1.04 billion, projecting blockbuster status. The company is advancing its pitolisant franchise with new formulations and indications, including an NDA submission for pitolisant GR in Q2 2026, and progressing a robust late-stage pipeline with five ongoing Phase 3 trials and a Phase 1 trial for an orexin-2 agonist. These strategic initiatives aim to extend the pitolisant lifecycle into the 2040s and target broader CNS indications.
